Notice | Nanologica

NOTICE CONVENING THE ANNUAL GENERAL MEETING OF NANOLOGICA AB (PUBL)

21 April, 2026

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby summoned to the Annual General Meeting on Thursday 21 May 2026, at 10.00 CET, at Advokatfirman Lindahl’s premises at Smålandsgatan 16, Stockholm. Right to attend the meetingShareholders who wish to participate in the Annual General Meeting must: be registered in their own name in the share register maintained by Euroclear Sweden AB on Wednesday 12 May 2026, notify the Company of its participation

KALLELSE TILL ÅRSSTÄMMA I NANOLOGICA AB (PUBL)

21 April, 2026

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 21 maj 2026, klockan 10.00, i Advokatfirman Lindahls lokaler på Smålandsgatan 16, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 12 maj 2026, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast fredagen den 15 maj

KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)

30 January, 2026

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till extra bolagsstämma onsdagen den 4 mars 2026, klockan 10.00, i Advokatfirman Lindahls lokaler, på Smålandsgatan 16, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i bolagsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 24 februari 2026, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast torsdagen den 26

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

30 January, 2026

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby invited to attend the Extraordinary General Meeting to be held on Wednesday, March 4, 2026, at 10.00 a.m. CET at Advokatfirman Lindahl's premises, at Smålandsgatan 16, Stockholm. Right to participate in the meeting Shareholders who wish to participate in the Extraordinary General Meeting must: be registered in their own name (not nominee-registered) in the share register maintained by Euroclear Sweden AB on Tuesday,

NOTICE CONVENING THE ANNUAL GENERAL MEETING OF NANOLOGICA AB (PUBL)

16 April, 2025

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby summoned to the Annual General Meeting on Thursday 22 May 2025, at 12.00 CET, at Advokatfirman Lindahl’s premises at Smålandsgatan 16, Stockholm. English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take precedence. Right to attend the meeting Shareholders who wish to participate in the Annual General Meeting must: be

KALLELSE TILL ÅRSSTÄMMA I NANOLOGICA AB (PUBL)

16 April, 2025

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 22 maj 2025, klockan 12.00, i Advokatfirman Lindahls lokaler på Smålandsgatan 16, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken onsdagen den 14 maj 2025, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast fredagen den 16 maj

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.